keyword
MENU ▼
Read by QxMD icon Read
search

primary progressive multiple sclerosis

keyword
https://www.readbyqxmd.com/read/29331092/deep-grey-matter-volume-loss-drives-disability-worsening-in-multiple-sclerosis
#1
Arman Eshaghi, Ferran Prados, Wallace Brownlee, Daniel R Altmann, Carmen Tur, M Jorge Cardoso, Floriana De Angelis, Steven H van de Pavert, Niamh Cawley, Nicola De Stefano, M Laura Stromillo, Marco Battaglini, Serena Ruggieri, Claudio Gasperini, Massimo Filippi, Maria A Rocca, Alex Rovira, Jaume Sastre-Garriga, Hugo Vrenken, Cyra E Leurs, Joep Killestein, Lukas Pirpamer, Christian Enzinger, Sebastien Ourselin, Claudia A M Gandini Wheeler-Kingshott, Declan Chard, Alan J Thompson, Daniel C Alexander, Frederik Barkhof, Olga Ciccarelli
OBJECTIVE: Grey matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS. METHODS: We analysed 3,604 brain high-resolution T1-weighted MRI scans from 1,417 participants: 1,214 MS patients (253 clinically-isolated syndrome[CIS], 708 relapsing-remitting[RRMS], 128 secondary-progressive[SPMS], 125 primary-progressive[PPMS]), over an average follow-up of 2...
January 13, 2018: Annals of Neurology
https://www.readbyqxmd.com/read/29331073/cerebrospinal-fluid-macrophage-biomarkers-in-amyotrophic-lateral-sclerosis
#2
A G Thompson, E Gray, M-L Thézénas, P D Charles, S Evetts, M T Hu, K Talbot, R Fischer, B M Kessler, M R Turner
Objective The neurodegenerative disease amyotrophic lateral sclerosis (ALS) is a heterogeneous clinical syndrome involving multiple molecular pathways. The development of biomarkers for use in therapeutic trials is a priority. We sought to use a high-throughput proteomic method to identify novel biomarkers in individual cerebrospinal fluid samples. Methods Liquid chromatography-tandem mass spectrometry with label-free quantification was used to identify cerebrospinal fluid proteins using samples from a well-characterised longitudinal cohort comprising patients with ALS (n=43), the upper motor neuron variant primary lateral sclerosis (PLS, n=6), cross-sectional healthy (n=20) and disease controls (Parkinsons's n=20, ALS mimic disorders n=12)...
January 13, 2018: Annals of Neurology
https://www.readbyqxmd.com/read/29324249/disability-in-progressive-ms-is-associated-with-t2-lesion-changes
#3
C Ammitzbøll, T B Dyrby, M Lyksborg, K Schreiber, R Ratzer, J Romme Christensen, P Iversen, M Magyari, E Garde, P S Sørensen, H R Siebner, F Sellebjerg
BACKGROUND: Progressive multiple sclerosis (MS) is characterised by diffuse changes on brain magnetic resonance imaging (MRI), which complicates the use of MRI as a diagnostic and prognostic marker. The relationship between MRI measures (conventional and non-conventional) and clinical disability in progressive MS therefore warrants further investigation. OBJECTIVE: To investigate the relationship between clinical disability and MRI measures in patients with progressive MS...
December 18, 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29318029/thrombin-generation-correlates-with-disease-duration-in-multiple-sclerosis-ms-novel-insights-into-the-ms-associated-prothrombotic-state
#4
Martin Em Parsons, Karen O'Connell, Seamus Allen, Karl Egan, Paulina B Szklanna, Christopher McGuigan, Fionnuala Ní Áinle, Patricia B Maguire
Background: Thrombin is well recognised for its role in the coagulation cascade but it also plays a role in inflammation, with enhanced thrombin generation observed in several inflammatory disorders. Although patients with multiple sclerosis (MS) have a higher incidence of thrombotic disease, thrombin generation has not been studied to date. Objectives: The aim of this study was to characterise calibrated automated thrombography parameters in patients with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS) in comparison to healthy controls (HCs)...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29316044/global-transcriptome-profiling-of-mild-relapsing-remitting-versus-primary-progressive-multiple-sclerosis
#5
Marcus W Koch, Yaroslav Ilnytskyy, Andrey Golubov, Luanne M Metz, V Wee Yong, Olga Kovalchuk
BACKGROUND: Genetic research in MS mostly compares MS patients with healthy controls, but does not differentiate between MS disease courses. We compared peripheral blood gene expression patterns between extremes of MS phenotypes: patients with mild relapsing-remitting MS (mRRMS) and primary progressive MS (PPMS). METHODS: We analyzed global gene expression profiles of peripheral blood samples of age and gender matched patients with mRRMS and PPMS. Detailed bioinformatic and gene set enrichment analysis, pathway and principle component analyses were used to identify differentially expressed genes and pathways...
January 8, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29289971/quality-of-life-and-social-support-in-patients-with-multiple-sclerosis
#6
Katarzyna Rosiak, Paweł Zagożdżon
OBJECTIVES: Quality of life and needforsocial support in persons diagnosed with multiple sclerosis (MS) are to a large extent determined by the degree of their disability. The aim of the study was to analyze an association between specific forms of MS, subjectively perceived quality of life and social support. METHODS: The study included subjects with established diagnosis of MS, treated at rehabilitation centers, hospitals and in a home setting, as well as the members of patient organizations...
October 29, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/29284602/cervical-cord-atrophy-and-long-term-disease-progression-in-patients-with-primary-progressive-multiple-sclerosis
#7
F X Aymerich, C Auger, J Alonso, M Alberich, J Sastre-Garriga, M Tintoré, X Montalban, A Rovira
BACKGROUND AND PURPOSE: Cervical cord atrophy has been associated with clinical disability in multiple sclerosis and is proposed as an outcome measure of neurodegeneration. The aim of this study was to quantify the development of cervical cord atrophy and to evaluate its association with disability progression in patients with primary-progressive multiple sclerosis. MATERIALS AND METHODS: Thirty-one patients with primary-progressive multiple sclerosis underwent 1...
December 28, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/29284493/impact-on-healthcare-resource-utilization-of-multiple-sclerosis-in-spain
#8
Antoni Sicras-Mainar, Elena Ruíz-Beato, Ruth Navarro-Artieda, Jorge Maurino
BACKGROUND: Multiple sclerosis (MS) is a chronic disease with a high socioeconomic impact. The aim of this study was to assess healthcare resources utilization and costs in a sample of patients with MS. METHODS: A retrospective, cohort study was conducted using electronic medical records from 19 primary care centres in Asturias and Catalonia, Spain. Adult patients diagnosed with MS were distributed into two groups according to the Expanded Disability Status Scale (EDSS) score: 0-3...
December 29, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/29282083/tissue-transglutaminase-in-astrocytes-is-enhanced-by-inflammatory-mediators-and-is-involved-in-the-formation-of-fibronectin-fibril-like-structures
#9
Nathaly Espitia Pinzón, John J P Brevé, John G J M Bol, Benjamin Drukarch, Wia Baron, Anne-Marie van Dam
BACKGROUND: During multiple sclerosis (MS) lesion formation, inflammatory mediators are produced by microglial cells and invading leukocytes. Subsequently, hypertrophic astrocytes fill the lesion and produce extracellular matrix (ECM) proteins that together form the astroglial scar. This is beneficial because it seals off the site of central nervous system (CNS) damage. However, astroglial scarring also forms an obstacle that inhibits remyelination of brain lesions. This is possibly an important cause for incomplete remyelination of the CNS in early stage MS patients and for failure of remyelination when the disease progresses...
December 28, 2017: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29276588/ventilatory-efficiency-and-aerobic-capacity-in-people-with-multiple-sclerosis-a-randomized-study
#10
Stine Maren Riksfjord, Siri Merete Brændvik, Ola D Røksund, Inger-Lise Aamot
Objectives: To assess ventilatory efficiency and aerobic capacity in people with multiple sclerosis and whether treadmill walking or progressive strength training has an effect on these parameters in this population. Methods: In all, 24 adults with multiple sclerosis with an Expanded Disability Status Scale score of ≤6 completed a cardiopulmonary exercise test before and after 8 weeks of exercise. They were randomized to treadmill walking of low-to-moderate intensity (50%-70% of peak heart rate) or progressive strength training (six repetitions × two at 80% of one repetition maximum)...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/29251340/-rituximab-its-efficacy-effectiveness-and-safety-in-the-treatment-of-multiple-sclerosis
#11
REVIEW
L Midaglia, L Mora, P Mulero, J Sastre-Garriga, X Montalban
INTRODUCTION: There is increasing evidence that B cells and humoral immunity play key roles in the pathogenesis of multiple sclerosis (MS). Ocrelizumab, an anti-CD20 monoclonal antibody, has been shown to be effective in controlling the disease and has recently been aproved by the Food and Drug Administration for the treatment of primary progressive and relapsing MS. While awaiting its marketing authorization, the use of rituximab, with a similar mechanism of action, has expanded widely in the area of demyelinating diseases...
January 1, 2018: Revista de Neurologia
https://www.readbyqxmd.com/read/29244240/b-cell-therapy-for-multiple-sclerosis-entering-an-era
#12
REVIEW
Ariele L Greenfield, Stephen L Hauser
Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). B cell depleting therapy is highly effective against relapsing forms of the disease, and is also the first treatment approach proven to protect against disability worsening in primary progressive MS. Moreover, evolving clinical experience with B cell therapy, combined with a more sophisticated understanding of humoral immunity in preclinical models and in patients with MS, have led to major progress in deciphering the immune pathogenesis of MS...
December 15, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/29234305/functional-components-of-cognitive-impairment-in-multiple-sclerosis-a-cross-sectional-investigation
#13
Jordi A Matias-Guiu, Ana Cortés-Martínez, María Valles-Salgado, Celia Oreja-Guevara, Vanesa Pytel, Paloma Montero, Teresa Moreno-Ramos, Jorge Matias-Guiu
Background: Cognitive impairment is frequent and disabling in multiple sclerosis (MS). Changes in information processing speed constitute the most important cognitive deficit in MS. However, given the clinical and topographical variability of the disease, cognitive impairment may vary greatly and appear in other forms in addition to slower information processing speed. Our aim was to determine the frequency of cognitive impairment, the principal cognitive domains, and components involved in MS and to identify factors associated with presence of cognitive impairment in these patients in a large series of patients...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/29232960/ocrelizumab-a-new-b-cell-therapy-for-relapsing-remitting-and-primary-progressive-multiple-sclerosis
#14
Amanda M Stahnke, Kathryn M Holt
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of ocrelizumab, a new B-cell-targeted therapy for multiple sclerosis (MS). DATA SOURCES: A comprehensive search of PubMed and OVID/MEDLINE was conducted using search terms ocrelizumab and multiple sclerosis using the date range of 1946 through October 2017. STUDY SELECTION AND DATA EXTRACTION: All English-language, human-subject articles related to ocrelizumab and MS were evaluated...
December 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29197515/fingolimod-anti-inflammatory-and-neuroprotective-effects-modulation-of-rage-axis-in-multiple-sclerosis-patients
#15
Zohara Sternberg, Channa Kolb, Kailash Chadha, Adam Nir, Raphael Nir, Rayan George, Joseph Johnson, Jinhee Yu, David Hojnacki
BACKGROUND: We investigated Fingolimod treatment effects on the RAGE (receptor for advanced glycation endproducts) axis in multiple sclerosis (MS) patients. The primary outcome of the study was whether Fingolimod treatment increases serum levels of the soluble RAGE isoforms, sRAGE and esRAGE - both being considered putative endogenous inhibitors of RAGE signaling. Additional variables were serum levels of RAGE ligands, the high mobility group box (HMGB)1 and pentosidine. METHODS: Serum levels of the study variables were measured by ELISA, and compared between baseline (before Fingolimod treatment) and 6 and 12 months post-drug treatment in 17 relapsing MS patients...
March 1, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29196354/multiple-sclerosis-a-treatable-disease%C3%A2
#16
Anisha Doshi, Jeremy Chataway
This article reviews our current understanding and modern treatment of multiple sclerosis (MS). MS is a disabling condition resulting in devastating social and economic impacts. As MS can affect any part of the central nervous system, the presentation is often diverse; however, there are key features that can be useful in the clinic. We comment on the diagnostic criteria and review the main subtypes of MS, including clinically isolated syndrome, relapsing remitting MS, secondary progressive MS and primary progressive MS...
December 2017: Clinical Medicine: Journal of the Royal College of Physicians of London
https://www.readbyqxmd.com/read/29193293/functional-antagonism-of-sphingosine-1-phosphate-receptor-1-prevents-cuprizone-induced-demyelination
#17
SunJa Kim, Jacek Bielawski, Hyunmin Yang, Yu Kong, Beiyan Zhou, Jianrong Li
Recent evidence suggests that the oral drug Fingolimod (FTY720) for relapsing-remitting multiple sclerosis (MS) may act directly on the central nervous system (CNS) and modulate disease pathogenesis and progression in experimental models of MS. However, the specific subtype of sphingosine-1-phosphate (S1P) receptors that mediates the effect of FTY720 on the CNS cells has not been fully elucidated. Here, we report that S1P receptor 1 (S1PR1) is elevated in reactive astrocytes in an autoimmunity independent mouse model of MS and that selective S1PR1 modulation is sufficient to ameliorate the loss of oligodendrocytes and demyelination...
November 29, 2017: Glia
https://www.readbyqxmd.com/read/29171579/common-clinical-features-of-pediatric-multiple-sclerosis-in-pakistan-a-report-of-15-cases
#18
Muhammad Arshad Javid, Khalida Mubeen, Mustansar Warraich Md, Niama Amin, Zahid Mehmood
The aim of this note is to assess the common clinical features of paediatric multiple sclerosis (PMS) in Pakistan. For this purpose, 150 MS patients with the age range of (1-72) years and mean age (34.2±11.09) years were studied during the period 2010 to 2015 from MRI centers of Pakistan. We found 15 paediatric MS cases which had clinical course relapsing-remitting MS (11), secondary-progressive MS (3) and primary-progressive MS (1). Revised McDonald criteria 2010 of MRI was used to disseminate lesions in space and time...
November 2017: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/29157397/progressive-forms-of-multiple-sclerosis-distinct-entity-or-age-dependent-phenomena
#19
REVIEW
Burcu Zeydan, Orhun H Kantarci
In multiple sclerosis (MS), disease course is defined by a subclinical or clinical relapsing remitting phase, a progressive phase, and the overlapping phase in-between. Each phase can have intermittently active or inactive periods. Subclinical activity in radiologically isolated syndrome evolving to primary-progressive MS is mostly indistinguishable from relapsing-remitting MS evolving to secondary-progressive MS. The onset of progressive-phase MS is age-dependent but time and pre-progressive phase agnostic...
February 2018: Neurologic Clinics
https://www.readbyqxmd.com/read/29143164/upregulation-of-myelin-gene-expression-by-a-physically-modified-saline-via-phosphatidylinositol-3-kinase-mediated-activation-of-creb-implications-for-multiple-sclerosis
#20
Malabendu Jana, Supurna Ghosh, Kalipada Pahan
An increase in central nervous system (CNS) remyelination and a decrease in CNS inflammation are important steps to halt the progression of multiple sclerosis (MS). RNS60 is a bioactive aqueous solution generated by subjecting normal saline to Taylor-Couette-Poiseuille flow under elevated oxygen pressure. Recently we have demonstrated that RNS60 exhibits anti-inflammatory properties. Here, we describe promyelinating property of RNS60. RNS60, but not normal saline (NS), RNS10.3 (TCP-modified saline without excess oxygen) or PNS60 (saline containing excess oxygen without TCP modification), stimulated the expression of myelin-specific genes and proteins (myelin basic protein, MBP; myelin oligodendrocyte glycoprotein, MOG and proteolipid protein, PLP) in primary mouse oligodendroglia and mixed glial cells...
November 15, 2017: Neurochemical Research
keyword
keyword
93616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"